Ciprofloxacin

Catalog No.S2027 Batch:S202701

Print

Technical Data

Formula

C17H18FN3O3
Molecular Weight 331.34 CAS No. 85721-33-1
Solubility (25°C)* In vitro 0.5MNAOH 3 mg/mL (9.05 mM)
DMSO Insoluble
Water Insoluble
In vivo (Add solvents to the product individually and in order)
Clear solution
5%0.1MNaOH 40%PEG300 5%Tween80 50%ddH2O

Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.

 0.15mg/ml (0.45mM) Taking the 1 mL working solution as an example, add 50 μL of 3 mg/ml clarified 0.1MNaOH stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution
5% 0.1MNaOH 95% Corn oil

Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.

 0.15mg/ml (0.45mM) Taking the 1 mL working solution as an example, add 50 μL of 3 mg/ml clear 0.1MNaOH stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Ciprofloxacin (Bay o 9867,Bay q 3939) is a fluoroquinolone antibiotic, shows broad and potent antibacterial activity, with MIC90 of 0.024-6 μM.
Targets
Topoisomerase IV [2]
In vitro

Ciprofloxacin is a fluoroquinolone antibiotic, shows MIC90 (minimal inhibitory concentrations for 90%) of between 0.008 and 2 μg/ml for Enterobacteriaceae, Pseudomonas aeruginosa, Haemophilus influenzae, Neisseria gonorrhoeae, streptococci, Staphylococcus aureus, and Bacteroidesfragilis strains. [1] Ciprofloxacin inhibits topoisomerase IV as a primary topoisomerase target and gyrase as a secondary target. [2] Ciprofloxacin shows an AUC (area under the curve) of 24 μg×h/ml[3]

Protocol (from reference)

Customer Product Validation

Data from [ Cancer Res , 2012 , 72(23), 6200-8 ]

Selleck's Ciprofloxacin has been cited by 2 publications

Targeting Intracellular Mycobacteria Using Nanosized Niosomes Loaded with Antibacterial Agents [ Nanomaterials (Basel), 2021, 11(8)1984] PubMed: 34443815
Predictions of genotoxic potential, mode of action, molecular targets, and potency via a tiered multiflow® assay data analysis strategy [ Environ Mol Mutagen, 2019, 60(6):513-533] PubMed: 30702769

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.